Do you have any questions? (088) 2080369 - 2345622 Pharmacy_QAAU@pharm.aun.edu.eg
The department announces that the lecture will be held on Thursday from 8:30 AM to 10:30 AM, and the practical session will take place from 8:30 AM to 12:00 PM. This is to ensure adherence to the schedule
The midterm exam for the "Entrepreneurship" course for Fifth-Year Pharm D students will take place on Thursday, March 13, 2025, starting at 12:00 PM in Hall (2) beneath the lecture halls.
By the will of God, the midterm exam for first-year Pharm D students (National University) in the Pharmaceutical Analytical Chemistry – 2 course will be held on Sunday, April 6, 2025, at 2:00 PM in Lecture Halls (A) and (B), as well as in Halls (1) and (2), on the following parts:-
1-Acid-base applications
2- Preciptimetry
By the will of God, the midterm exam for third-year students in the Scientific Writing course will be held on Monday, March 10, 2025, at 9:00 AM in the department's lecture hall and student laboratories.
By the will of God, the midterm exam for Clinical Pharmacy students, Semester (2), in the Pharmaceutical Analytical Chemistry – 2 course will be held on Wednesday, April 9, 2025, during the scheduled practical session on the following parts:
1-Acid-base applications
2- Preciptimetry
By the will of God, the midterm exam for third-year students in the Scientific Writing course will be held on Monday, March 17, 2025, at 9:00 AM in the department's lecture hall and student laboratories.
By the will of God, the midterm exam for Clinical Pharmacy students, Semester (6), in the Scientific Writing course will be held on Monday, March 17, 2025, from 1:00 PM to 2:00 PM during the scheduled lecture time in the department's laboratories.
Metformin hydrochloride (MTF) has pharmacological properties for managing inflammatory skin conditions. MTF is a hydrophilic medication. Accordingly, embedding MTF into lipid carriers for enhancing skin penetration presents a challenge. The study aims to optimize the loading of MTF into nanostructured lipid carriers (NLCs) using a 22 full factorial design, employing the solvent injection technique. The NLCs were evaluated for encapsulation efficiency, hydrodynamic diameter, zeta potential, and polydispersity index. Alkalinization of the aqueous phase (pH = 12.5) resulted in maximizing the entrapment of MTF within NLCs. Furthermore, the tested solid lipids impacted the encapsulation of MTF based on their hydrophilic-lipophilic balance. The optimized formulation is composed of a lipid phase incorporating beeswax (75 mg), oleic acid (25 mg), and Span 60 (1% w/w), and an aqueous phase comprised of 1% w/w Tween 80, pH 12.5. The selected formula attained an entrapment efficiency of 53.68 ± 0.27%, a particle size of 333.0 ± 6.4 nm, and a negative surface charge, indicating adequate particles` stability. DSC and Molecular docking analyses confirmed the MTF incorporation within the lipid phase. The outcomes emphasize the importance of optimizing investigations in developing a viable delivery system for MTF to boost its permeation across the skin layers
Rosuvastatin (ROS), a statin drug with promising anticancer properties has a low bioavailability of approximately 20% due to lipophilicity and first-pass metabolism. This study aimed to enhance ROS anticancer efficacy through loading into flexible chitosomes. The chitosomes were prepared starting from negatively charged liposomes through electrostatic interactions with chitosan. The conversion of zeta potential from negative to positive confirmed the successful formation of chitosomes. The chitosan coating increased the particle size and zeta potential, which ranged from 202.0 ± 1.7 nm to 504.7 ± 25.0 nm and from − 44.9 ± 3.0 mV to 50.1 ± 2.6 mV, respectively. Chitosan and drug concentrations had an important influence on the chitosome properties. The optimum chitosome formulation was used to prepare ROS-loaded flexible chitosomes using different concentrations of four edge activators. The type and concentration of edge activator influenced the particle size, drug entrapment efficiency, and drug release rate of the flexible chitosomes. Flexible chitosomes significantly increased drug permeation through rat abdominal skin compared to control transferosomes and drug solution. The optimal ROS flexible chitosomes containing sodium deoxycholate as an edge activator had a 2.23-fold increase in ROS cytotoxic efficacy against MCF7 cells and a 1.84-fold increase against HepG2 cells. These results underscore the potential of flexible chitosomes for enhancing ROS anticancer efficacy.
